` BSX (Boston Scientific Corp) vs S&P 500 Comparison - Alpha Spread

BSX
vs
S&P 500

Over the past 12 months, BSX has underperformed S&P 500, delivering a return of -34% compared to the S&P 500's +26% growth.

Stocks Performance
BSX vs S&P 500

Loading
BSX
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
BSX vs S&P 500

Loading
BSX
S&P 500
Difference
www.alphaspread.com

Performance By Year
BSX vs S&P 500

Loading
BSX
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Boston Scientific Corp vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Boston Scientific Corp
Glance View

In the world of medical devices, Boston Scientific Corp. has carved out a significant niche, navigating the intersection of innovation and healthcare with precision. Founded in 1979, the company has built a robust reputation for developing a diverse range of products that address complex medical conditions. Boston Scientific operates through various segments, primarily focusing on interventional medical specialties that target areas such as cardiology, endoscopy, and neuromodulation. Through its relentless pursuit of innovation, the company continues to push boundaries, enhancing the diagnostic and therapeutic capabilities of physicians worldwide. The heartbeat of its operations lies in its extensive research and development endeavors, where cutting-edge technology meets advanced medical knowledge to produce life-enhancing solutions. At its core, Boston Scientific makes money by designing, manufacturing, and selling medical devices used in minimally invasive procedures. Its product portfolio includes solutions for coronary artery disease, heart rhythm disorders, peripheral artery disease, and many other critical ailments. By partnering with healthcare providers, Boston Scientific enables hospitals and clinics to offer high-quality, efficient care that caters to patient needs in a cost-effective manner. Revenue streams flow through direct sales channels and strategic partnerships across global markets, reflecting a combination of organic growth and strategic acquisitions. Moreover, the company actively reinvests in future technologies, ensuring its position as a pioneer in medical advancements while meeting the ever-evolving demands of the industry.

BSX Intrinsic Value
69.64 USD
Undervaluation 11%
Intrinsic Value
Price $61.79
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett